Release Date: December 10, 2022
Expiration Date: February 27, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is intended for medical oncologists, hematologists, and pediatric hematologists who treat or manage patients with Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with Hodgkin lymphoma are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Devise strategies to personalize treatment of patients with HL based on patient-related factors, risk stratification and treatment history
- Evaluate the efficacy and safety profile for current/emerging therapies among patients with advanced HL from landmark clinical trials as well as real world data across therapy lines
- Develop strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with advanced HL
- Apply recent evidence from landmark trials in advanced HL to real-world scenarios encountered in the care of patients with this malignancy
David J. Straus, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: Bayer, DAVA Pharmaceuticals, Inc, Elselvier, Juno Pharmaceuticals Corp, Millennium Pharmaceuticals, Inc, ONCOtracker, Inc, Seagen Inc. Speakers’ Bureau: Roche.
Joseph M. Connors, MD, CM
Emeritus Professor, University of British Columbia
BC Cancer Centre for Lymphoid Cancer
Vancouver, BC, Canada
Disclosures: Joseph M. Connors, MD, CM has no relevant financial relationships with ineligible companies.
Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Institute of Hematology “L. e A. Seràgnoli” University of Bologna
Bologna, Italy
Disclosures: Consultant: AstraZeneca, BeiGene, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Inc, Incyte, Janssen, Kyowa Kirin, MSD, Novartis Pharmaceuticals Corporation, Roche, Takeda. Speakers’ Bureau: AstraZeneca, BeiGene, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Inc, Incyte, Janssen, Kyowa Kirin, MSD, Novartis Pharmaceuticals Corporation, Roche, Takeda
Sharon Castellino, MD, MSc
Professor of Pediatrics Emory University
Director, Leukemia/Lymphoma Program
The Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta
Atlanta, GA
Disclosures: Other: Seagen Inc (moderator, scientific advisory board, no honorarium received)
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
